These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9083299)

  • 1. Acute rejection of renal allografts: mechanistic insights and therapeutic options.
    Suthanthiran M
    Kidney Int; 1997 Apr; 51(4):1289-304. PubMed ID: 9083299
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunoadsorption in acute vascular rejection after renal transplantation.
    Persson NH; Bucin D; Ekberg H; Källén R; Omnell Persson M; Simanaitis M; Sterner G; Swedenborg P
    Transplant Proc; 1995 Dec; 27(6):3466. PubMed ID: 8540054
    [No Abstract]   [Full Text] [Related]  

  • 3. Functional role of atrial natriuretic peptide in acute renal transplant rejection.
    Naicker S; Moodley D; Nadar A; Gathiram P
    Immunopharmacology; 1996 Jun; 33(1-3):161-3. PubMed ID: 8856139
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of serum immunological parameters in acute renal allograft rejection.
    Yang J; Li XW; Zheng FL; Bi ZQ
    Transplant Proc; 1996 Jun; 28(3):1443-4. PubMed ID: 8658732
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen.
    Loss GE; Grewal HP; Siegel CT; Peace D; Mead J; Bruce DS; Cronin DC; Millis JM; Newell KA; Woodle ES
    Transplant Proc; 1998 Jun; 30(4):1249-50. PubMed ID: 9636508
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of matching for HLA-DR in first cadaveric renal transplantation in nonsensitized recipients.
    Reisaeter AV; Leivestad T; Fauchald P; Brekke I; Thorsby E
    Transplant Proc; 1997 Nov; 29(7):3099-100. PubMed ID: 9365682
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and immunologic characteristics of transplant recipients with recurrent acute rejection episodes.
    Jacobs U; Niese D; Brensing KA; Klein B; Buszello H; Klehr HU
    Transplant Proc; 1996 Dec; 28(6):3231-3. PubMed ID: 8962250
    [No Abstract]   [Full Text] [Related]  

  • 9. Histopathologic detection of rejection in acute allograft pyelonephritis.
    Mohamed N; Aggarwal V; Cole E; John R
    Transplantation; 2012 Oct; 94(7):e46-7. PubMed ID: 23038631
    [No Abstract]   [Full Text] [Related]  

  • 10. Review: Management of patients with kidney allograft failure.
    Bunthof KLW; Hazzan M; Hilbrands LB
    Transplant Rev (Orlando); 2018 Jul; 32(3):178-186. PubMed ID: 29628415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK506 rescue therapy for acute renal allograft rejection.
    Goh BL; Morad Z; Cheah PL; Chua CT; Tan SY
    Transplant Proc; 1998 Nov; 30(7):3592-3. PubMed ID: 9838574
    [No Abstract]   [Full Text] [Related]  

  • 13. Rejection after kidney transplantation: new concepts, new therapeutic options.
    van der Woude FJ; Hollander AA
    Transplant Proc; 1998 Aug; 30(5):2419-24. PubMed ID: 9723523
    [No Abstract]   [Full Text] [Related]  

  • 14. Early recognition of rejections in kidney transplant recipients: applying tests for kidney-derived urinary antigens.
    Limberg R; Koch C; Livni E; Shaharabani E; Shapira Z; Falkenberg FW
    Kidney Int Suppl; 1994 Nov; 47():S97-100. PubMed ID: 7869679
    [No Abstract]   [Full Text] [Related]  

  • 15. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.
    DeVos JM; Gaber AO; Knight RJ; Land GA; Suki WN; Gaber LW; Patel SJ
    Kidney Int; 2012 Sep; 82(5):598-604. PubMed ID: 22622504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of renal allograft rejection: new therapeutic approaches and new insights into established therapies.
    Lu CY; Sicher SC; Vazquez MA
    J Am Soc Nephrol; 1993 Dec; 4(6):1239-56. PubMed ID: 8130352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
    Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
    Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
    [No Abstract]   [Full Text] [Related]  

  • 18. Methotrexate is effective in preventing acute and potentially chronic renal allograft rejection.
    Michael B; Francos GC; Burke JF; Gaughan WI
    Transplant Proc; 1994 Oct; 26(5):3046-7. PubMed ID: 7940956
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection.
    Ahmed T; Senzel L
    J Clin Apher; 2012; 27(4):173-7. PubMed ID: 22411078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
    Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
    Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.